-
Je něco špatně v tomto záznamu ?
Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder Cancer
L. Afferi, C. Lonati, F. Montorsi, A. Briganti, A. Necchi, A. Mari, A. Minervini, R. Tellini, R. Campi, GB. Schulz, PC. Black, E. di Trapani, O. de Cobelli, RJ. Karnes, M. Ahmed, MC. Mir, MA. Algarra, M. Rink, S. Zamboni, F. Mondini, C. Simeone,...
Jazyk angličtina Země Nizozemsko
Typ dokumentu multicentrická studie, časopisecké články
- MeSH
- adjuvantní chemoterapie MeSH
- cisplatina terapeutické užití MeSH
- cystektomie * škodlivé účinky MeSH
- lidé MeSH
- močový měchýř patologie MeSH
- nádory močového měchýře * farmakoterapie chirurgie patologie MeSH
- retrospektivní studie MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
A trend towards greater benefit from adjuvant chemotherapy (ACT) in pN+ bladder cancer (BCa) has been observed in multiple randomized controlled trials. However, it is still unclear which patients might benefit the most from this approach. We retrospectively analyzed a multicenter cohort of 1381 patients with pTany pN1-3 cM0 R0 urothelial BCa treated with radical cystectomy (RC) with or without cisplatin-based ACT. The main endpoint was overall survival (OS) after RC. We performed 1:1 propensity score matching to adjust for baseline characteristics and conducted a classification and regression tree (CART) analysis to assess postoperative risk groups and Cox regression analyses to predict OS. Overall, 391 patients (28%) received cisplatin-based ACT. After matching, two cohorts of 281 patients with pN+ BCa were obtained. CART analysis stratified patients into three risk groups: favorable prognosis (≤pT2 and positive lymph node [PLN] count ≤2; odds ratio [OR] 0.43), intermediate prognosis (≥pT3 and PLN count ≤2; OR 0.92), and poor prognosis (pTany and PLN count ≥3; OR 1.36). Only patients with poor prognosis benefitted from ACT in terms of OS (HR 0.51; p < 0.001). We created the first algorithm that stratifies patients with pN+ BCa into prognostic classes and identified patients with pTany BCa with PLN ≥3 as the most suitable candidates for cisplatin-based ACT. PATIENT SUMMARY: We found that overall survival among patients with bladder cancer and evidence of lymph node involvement depends on cancer stage and the number of positive lymph nodes. Patients with more than three nodes affected by metastases seem to experience the greatest overall survival benefit from cisplatin-based chemotherapy after bladder removal. Our study suggests that patients with the highest risk should be prioritized for cisplatin-based chemotherapy after bladder removal.
Clinica Luganese Moncucco Lugano Switzerland
Clinica Sant'Anna Swiss Medical Group Sorengo Switzerland
Department of Experimental and Clinical Medicine University of Florence Florence Italy
Department of Medical Oncology San Raffaele Scientific Institute Milan Italy
Department of Oncology and Hematology Oncology Università degli Studi di Milano Milan Italy
Department of Surgical and Diagnostic Integrated Sciences University of Genova Genova Italy
Department of Urologic Science University of British Columbia Vancouver BC Canada
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology and Oncologic Urology Wrocław Medical University Wrocław Poland
Department of Urology Bichat Claude Bernard Hospital Paris University Paris France
Department of Urology CHU Toulouse IUCT Oncopole Toulouse France
Department of Urology European Institute of Oncology IRCCS Milan Italy
Department of Urology Foundation Instituto Valenciano Oncologia Valencia Spain
Department of Urology Institut Mutualiste Montsouris and Université Paris Descartes Paris France
Department of Urology La Paz University Hospital Madrid Spain
Department of Urology Luzerner Kantonsspital Lucerne Switzerland
Department of Urology Mayo Clinic Rochester MN USA
Department of Urology München Klinik Bogenhausen Munich Germany
Department of Urology Ruhr University Bochum Marien Hospital Herne Germany
Department of Urology Spedali Civili Hospital University of Brescia Brescia Italy
Department of Urology University Hospital of Munich Munich Germany
Department of Urology University Hospital Zürich University of Zürich Zürich Switzerland
Department of Urology University Medical Center Hamburg Eppendorf Hamburg Germany
Department of Urology University of Texas Southwestern Medical Center Dallas TX USA
Department of Urology University of Verona Verona Italy
Department of Urology Urological Research Institute San Raffaele Scientific Institute Milan Italy
Department of Urology Weill Cornell Medical College New York Presbyterian Hospital New York NY USA
Instituto de Investigación Hospital Universitario La Paz Madrid Spain
S H Ho Urology Department of Surgery The Chinese University of Hong Kong Hong Kong China
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032504
- 003
- CZ-PrNML
- 005
- 20230131151900.0
- 007
- ta
- 008
- 230120s2022 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.euo.2022.04.001 $2 doi
- 035 __
- $a (PubMed)35715319
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Afferi, Luca $u Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. Electronic address: luca.afferi@gmail.com
- 245 10
- $a Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder Cancer / $c L. Afferi, C. Lonati, F. Montorsi, A. Briganti, A. Necchi, A. Mari, A. Minervini, R. Tellini, R. Campi, GB. Schulz, PC. Black, E. di Trapani, O. de Cobelli, RJ. Karnes, M. Ahmed, MC. Mir, MA. Algarra, M. Rink, S. Zamboni, F. Mondini, C. Simeone, A. Antonelli, A. Tafuri, W. Krajewski, B. Małkiewicz, E. Xylinas, F. Soria, R. Sanchez Salas, A. Arora, X. Cathelineau, K. Hendricksen, M. Ammiwala, M. Borghesi, F. Chierigo, JY. Teoh, A. Mattei, S. Albisinni, F. Roghmann, M. Roumiguié, AS. Bajeot, E. Maier, A. Aziz, R. Hurle, R. Contieri, B. Pradere, R. Carando, C. Poyet, M. Alvarez-Maestro, D. D'Andrea, SF. Shariat, M. Moschini, European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group
- 520 9_
- $a A trend towards greater benefit from adjuvant chemotherapy (ACT) in pN+ bladder cancer (BCa) has been observed in multiple randomized controlled trials. However, it is still unclear which patients might benefit the most from this approach. We retrospectively analyzed a multicenter cohort of 1381 patients with pTany pN1-3 cM0 R0 urothelial BCa treated with radical cystectomy (RC) with or without cisplatin-based ACT. The main endpoint was overall survival (OS) after RC. We performed 1:1 propensity score matching to adjust for baseline characteristics and conducted a classification and regression tree (CART) analysis to assess postoperative risk groups and Cox regression analyses to predict OS. Overall, 391 patients (28%) received cisplatin-based ACT. After matching, two cohorts of 281 patients with pN+ BCa were obtained. CART analysis stratified patients into three risk groups: favorable prognosis (≤pT2 and positive lymph node [PLN] count ≤2; odds ratio [OR] 0.43), intermediate prognosis (≥pT3 and PLN count ≤2; OR 0.92), and poor prognosis (pTany and PLN count ≥3; OR 1.36). Only patients with poor prognosis benefitted from ACT in terms of OS (HR 0.51; p < 0.001). We created the first algorithm that stratifies patients with pN+ BCa into prognostic classes and identified patients with pTany BCa with PLN ≥3 as the most suitable candidates for cisplatin-based ACT. PATIENT SUMMARY: We found that overall survival among patients with bladder cancer and evidence of lymph node involvement depends on cancer stage and the number of positive lymph nodes. Patients with more than three nodes affected by metastases seem to experience the greatest overall survival benefit from cisplatin-based chemotherapy after bladder removal. Our study suggests that patients with the highest risk should be prioritized for cisplatin-based chemotherapy after bladder removal.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a cystektomie $x škodlivé účinky $7 D015653
- 650 _2
- $a cisplatina $x terapeutické užití $7 D002945
- 650 _2
- $a močový měchýř $x patologie $7 D001743
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a výsledek terapie $7 D016896
- 650 12
- $a nádory močového měchýře $x farmakoterapie $x chirurgie $x patologie $7 D001749
- 650 _2
- $a adjuvantní chemoterapie $7 D017024
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Lonati, Chiara $u Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland; Department of Urology, Spedali Civili Hospital, University of Brescia, Brescia, Italy
- 700 1_
- $a Montorsi, Francesco $u Department of Urology, Urological Research Institute, San Raffaele Scientific Institute, Milan, Italy
- 700 1_
- $a Briganti, Alberto $u Department of Urology, Urological Research Institute, San Raffaele Scientific Institute, Milan, Italy
- 700 1_
- $a Necchi, Andrea $u Department of Medical Oncology, San Raffaele Scientific Institute, Milan, Italy
- 700 1_
- $a Mari, Andrea $u Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
- 700 1_
- $a Minervini, Andrea $u Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
- 700 1_
- $a Tellini, Riccardo $u Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
- 700 1_
- $a Campi, Riccardo $u Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
- 700 1_
- $a Schulz, Gerald Bastian $u Department of Urology, University Hospital of Munich, Munich, Germany; Department of Urologic Science, University of British Columbia, Vancouver, BC, Canada
- 700 1_
- $a Black, Peter C $u Department of Urologic Science, University of British Columbia, Vancouver, BC, Canada
- 700 1_
- $a di Trapani, Ettore $u Department of Urology, European Institute of Oncology IRCCS, Milan, Italy
- 700 1_
- $a de Cobelli, Ottavio $u Department of Urology, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology, Università degli Studi di Milano, Milan, Italy
- 700 1_
- $a Karnes, R Jeffrey $u Department of Urology, Mayo Clinic, Rochester, MN, USA
- 700 1_
- $a Ahmed, Mohamed $u Department of Urology, Mayo Clinic, Rochester, MN, USA
- 700 1_
- $a Mir, M Carmen $u Department of Urology, Foundation Instituto Valenciano Oncologia, Valencia, Spain
- 700 1_
- $a Algarra, Maria Asuncion $u Department of Urology, Foundation Instituto Valenciano Oncologia, Valencia, Spain
- 700 1_
- $a Rink, Michael $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Zamboni, Stefania $u Department of Urology, Spedali Civili Hospital, University of Brescia, Brescia, Italy
- 700 1_
- $a Mondini, Francesca $u Department of Urology, Spedali Civili Hospital, University of Brescia, Brescia, Italy
- 700 1_
- $a Simeone, Claudio $u Department of Urology, Spedali Civili Hospital, University of Brescia, Brescia, Italy
- 700 1_
- $a Antonelli, Alessandro $u Department of Urology, University of Verona, Verona, Italy
- 700 1_
- $a Tafuri, Alessandro $u Department of Urology, University of Verona, Verona, Italy
- 700 1_
- $a Krajewski, Wojciech $u Department of Urology and Oncologic Urology, Wrocław Medical University, Wrocław, Poland
- 700 1_
- $a Małkiewicz, Bartosz $u Department of Urology and Oncologic Urology, Wrocław Medical University, Wrocław, Poland
- 700 1_
- $a Xylinas, Evanguelos $u Department of Urology, Bichat-Claude Bernard Hospital, Paris University, Paris, France
- 700 1_
- $a Soria, Francesco $u Division of Urology, Department of Surgical Sciences, AOU Città della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy
- 700 1_
- $a Sanchez Salas, Rafael $u Department of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France
- 700 1_
- $a Arora, Amandeep $u Department of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France
- 700 1_
- $a Cathelineau, Xavier $u Department of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France
- 700 1_
- $a Hendricksen, Kees $u Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
- 700 1_
- $a Ammiwala, Maida $u Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
- 700 1_
- $a Borghesi, Marco $u Department of Surgical and Diagnostic Integrated Sciences, University of Genova, Genova, Italy
- 700 1_
- $a Chierigo, Francesco $u Department of Surgical and Diagnostic Integrated Sciences, University of Genova, Genova, Italy
- 700 1_
- $a Teoh, Jeremy Yuen-Chun $u S.H. Ho Urology, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China
- 700 1_
- $a Mattei, Agostino $u Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland
- 700 1_
- $a Albisinni, Simone $u Department of Urology, University Clinics of Brussels, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
- 700 1_
- $a Roghmann, Florian $u Department of Urology, Ruhr-University Bochum, Marien Hospital, Herne, Germany
- 700 1_
- $a Roumiguié, Mathieu $u Department of Urology, CHU Toulouse-IUCT Oncopole, Toulouse, France
- 700 1_
- $a Bajeot, Anne Sophie $u Department of Urology, CHU Toulouse-IUCT Oncopole, Toulouse, France
- 700 1_
- $a Maier, Elisabeth $u Department of Urology, München Klinik Bogenhausen, Munich, Germany
- 700 1_
- $a Aziz, Atiqullah $u Department of Urology, München Klinik Bogenhausen, Munich, Germany
- 700 1_
- $a Hurle, Rodolfo $u Department of Urology, Istituto Clinico Humanitas IRCCS Clinical and Research Hospital, Rozzano, Milan, Italy
- 700 1_
- $a Contieri, Roberto $u Department of Urology, Istituto Clinico Humanitas IRCCS Clinical and Research Hospital, Rozzano, Milan, Italy
- 700 1_
- $a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria
- 700 1_
- $a Carando, Roberto $u Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland; Clinica Luganese Moncucco, Lugano, Switzerland; Clinica Sant'Anna, Swiss Medical Group, Sorengo, Switzerland
- 700 1_
- $a Poyet, Cedric $u Department of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland
- 700 1_
- $a Alvarez-Maestro, Mario $u Department of Urology, La Paz University Hospital, Madrid, Spain; Instituto de Investigación Hospital Universitario La Paz, Madrid, Spain
- 700 1_
- $a D'Andrea, David $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Moschini, Marco $u Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland; Department of Urology, Urological Research Institute, San Raffaele Scientific Institute, Milan, Italy
- 710 2_
- $a European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group
- 773 0_
- $w MED00205913 $t European urology oncology $x 2588-9311 $g Roč. 5, č. 6 (2022), s. 722-725
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35715319 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131151855 $b ABA008
- 999 __
- $a ok $b bmc $g 1891329 $s 1183839
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 5 $c 6 $d 722-725 $e 20220615 $i 2588-9311 $m European urology oncology $n Eur Urol Oncol $x MED00205913
- LZP __
- $a Pubmed-20230120
